# 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

> **NCT03538743** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 98 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961
- **DRUG:** PF-06882961

## Key facts

- **NCT ID:** NCT03538743
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-25
- **Primary completion:** 2019-05-23
- **Final completion:** 2019-06-10
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03538743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03538743, "4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03538743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*